The Public Record
Joseph R. Pitts is a former Republican member of the U.S. House of Representatives, serving Pennsylvania's 16th congressional district from 1997 to 2017. During his tenure, Pitts was known for his focus on healthcare, energy, and family issues, often advocating for conservative policies. He played a significant role in various legislative efforts, including those related to the Affordable Care Act and energy independence. Pitts was also involved with the Pennsylvania Family Institute, reflecting his commitment to family values and social issues.
For over five decades now, the Chinese Communist Party has ruled Tibet harshly and has treated the Tibetan people with great disdain. The current regime says that Tibet is open to all visitors, but the truth is that actual access is highly…
It is absolutely stunning that this Administration, nearly a year after launch of the exchanges and with $1 trillion on the line, has yet to build a functioning eligibility system.
I really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in this research and perhaps have a more effective therapy.
Today's hearing provides us with an opportunity to examine perhaps one of the most important aspects of the 21st Century Cures Initiative.
This expensive and antiquated clinical trials model is simply not acceptable in the 21st century.
I am pleased to ask all of the Members to support this commonsense bill that is on behalf of the life and safety of our animal patients and the safety of our food supply. I urge bipartisan support, and I yield back the balance of my time…
I would like to include an exchange of letters between the Committee on Energy and Commerce and the Committee on the Judiciary. House of Representatives, Committee on the Judiciary, Washington, DC, April 28, 2014. Hon. Fred Upton…
Part of the work of our 21st Century Cures Initiative is to identify existing roadblocks to speeding treatments and cures to patients.
This is another piece of important legislation, and it enjoys bipartisan support. I urge the Members to support it. I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from…
I urge support, again, for this important and bipartisan legislation, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Pennsylvania (Mr. Pitts) that the House…
At this time, I yield 5 minutes to the gentleman from New Jersey, Congressman Chris Smith, the distinguished prime sponsor of the legislation, who has really provided the leadership on this issue.
At this time I yield 1 minute to the distinguished gentleman from Florida (Mr. Bilirakis), a valued member of the Health Subcommittee.
I also urge Members to support this commonsense legislation, bipartisanly supported. I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Pennsylvania (Mr. Pitts) that…
I am very pleased to support this very important bipartisan legislation. I urge all Members to do so, and I yield back the balance of my time.
Again, Mr. Speaker, H.R. 4080 is another very important and bipartisan bill, and I urge all of the Members to support it. I yield back the balance of my time. The SPEAKER pro tempore (Mr. Jolly). The question is on the motion offered by…
I think it is unacceptable that the administration continues to give Americans the false impression that this promise is somehow true.
As a result, many plans are turning to narrower provider networks and skimpier prescription drug coverage to keep premiums and deductibles in check.
The President's health care law was sold to the American people with a number of promises: If you like your plan, you will be able to keep it; if you like your doctor, you will be able to continue seeing him or her.
I am particularly interested in better understanding what we can do to make it more attractive for companies and venture capitalists to invest.
the cost of developing a drug has doubled, as has the number of clinical trials necessary to file a new drug application.
To help close this innovation gap, as part of 21st Century Cures Initiative, we must take a fresh look at the challenges facing innovative companies and make certain the right incentives are in place so America is home to the next…
After all, as we have learned, there are only effective treatments for 500 of the 7,000 known diseases impacting patients today.
The cost of developing a drug has doubled, as has the number of clinical trials necessary to file a new drug application.
Politicians like Joe Pitts
